HUE042239T2 - Tamoxifen deriváltok neoplasztikus betegségek gyógyításához, fõként magasabb HER2 proteinszinttel - Google Patents

Tamoxifen deriváltok neoplasztikus betegségek gyógyításához, fõként magasabb HER2 proteinszinttel

Info

Publication number
HUE042239T2
HUE042239T2 HUE14721738A HUE14721738A HUE042239T2 HU E042239 T2 HUE042239 T2 HU E042239T2 HU E14721738 A HUE14721738 A HU E14721738A HU E14721738 A HUE14721738 A HU E14721738A HU E042239 T2 HUE042239 T2 HU E042239T2
Authority
HU
Hungary
Prior art keywords
higher levels
neoplastic diseases
her2 protein
treat neoplastic
tamoxifen derivatives
Prior art date
Application number
HUE14721738A
Other languages
English (en)
Hungarian (hu)
Inventor
Jiri Neuzil
Jan Stursa
Lukas Werner
Original Assignee
Smart Brain Sro
Biotechnologicky Ustav Av Cr V V I
Kkcg Ag
Jiri Neuzil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50677895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE042239(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CZ2013-308A external-priority patent/CZ2013308A3/cs
Priority claimed from CZ2014-66A external-priority patent/CZ305571B6/cs
Application filed by Smart Brain Sro, Biotechnologicky Ustav Av Cr V V I, Kkcg Ag, Jiri Neuzil filed Critical Smart Brain Sro
Publication of HUE042239T2 publication Critical patent/HUE042239T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5449—Polyphosphonium compounds
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C09B23/0025—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain the substituent being bound through an oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/14—Styryl dyes
    • C09B23/141—Bis styryl dyes containing two radicals C6H5-CH=CH-
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/001—Dyes containing an onium group attached to the dye skeleton via a bridge
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/008—Dyes containing a substituent, which contains a silicium atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
HUE14721738A 2013-04-24 2014-04-07 Tamoxifen deriváltok neoplasztikus betegségek gyógyításához, fõként magasabb HER2 proteinszinttel HUE042239T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2013-308A CZ2013308A3 (cs) 2013-04-24 2013-04-24 Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2
CZ2014-66A CZ305571B6 (cs) 2014-01-29 2014-01-29 Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2

Publications (1)

Publication Number Publication Date
HUE042239T2 true HUE042239T2 (hu) 2019-06-28

Family

ID=50677895

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14721738A HUE042239T2 (hu) 2013-04-24 2014-04-07 Tamoxifen deriváltok neoplasztikus betegségek gyógyításához, fõként magasabb HER2 proteinszinttel

Country Status (21)

Country Link
US (1) US9896466B2 (cg-RX-API-DMAC10.html)
EP (1) EP2989110B1 (cg-RX-API-DMAC10.html)
JP (1) JP6375091B2 (cg-RX-API-DMAC10.html)
KR (1) KR101764991B1 (cg-RX-API-DMAC10.html)
CN (1) CN105452265B (cg-RX-API-DMAC10.html)
AU (1) AU2014256546B2 (cg-RX-API-DMAC10.html)
CA (1) CA2909994C (cg-RX-API-DMAC10.html)
CY (1) CY1120821T1 (cg-RX-API-DMAC10.html)
DK (1) DK2989110T3 (cg-RX-API-DMAC10.html)
EA (1) EA029881B1 (cg-RX-API-DMAC10.html)
ES (1) ES2699099T3 (cg-RX-API-DMAC10.html)
GE (2) GEAP201813996A (cg-RX-API-DMAC10.html)
HR (1) HRP20181872T1 (cg-RX-API-DMAC10.html)
HU (1) HUE042239T2 (cg-RX-API-DMAC10.html)
MD (1) MD4626C1 (cg-RX-API-DMAC10.html)
NZ (1) NZ713589A (cg-RX-API-DMAC10.html)
PL (1) PL2989110T3 (cg-RX-API-DMAC10.html)
PT (1) PT2989110T (cg-RX-API-DMAC10.html)
SI (1) SI2989110T1 (cg-RX-API-DMAC10.html)
UA (1) UA116469C2 (cg-RX-API-DMAC10.html)
WO (1) WO2014173374A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10548318B2 (en) * 2015-07-03 2020-02-04 Bayer Cropscience Aktiengesellschaft N-(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamide derivatives with herbicidal action
CN107709317B (zh) * 2015-07-03 2021-05-11 拜耳作物科学股份公司 具有除草作用的n-(1,3,4-噁二唑-2-基)芳基甲酰胺衍生物
HK1257296A1 (zh) * 2016-07-12 2019-10-18 Accutar Biotechnology Inc. 新的化合物及其用途
EP3484463B1 (en) 2016-08-19 2020-02-12 The United States of America, as Represented by The Secretary, Department of Health and Human Services Office of Technology Transfer Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
EP3330274A1 (en) * 2016-12-01 2018-06-06 Springtide Ventures s.r.o. Compounds for treatment of senescence-related disorders
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン：癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
WO2019083997A1 (en) 2017-10-24 2019-05-02 Lunella Biotech, Inc. MITOFLAVOSCINS: TARGETING FLAVIN-CONTAINING ENZYMES THAT REMOVE CANCER STEM CELLS (CSC) BY INHIBITING MITOCHONDRIAL BREATHING
CR20200238A (es) 2017-11-24 2020-12-04 Lunella Biotech Inc Compuestos derivados de trifenilfosfonio para erradicar células madre cancerosas
CA3083487A1 (en) 2017-12-01 2019-06-06 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
US11541120B2 (en) 2017-12-05 2023-01-03 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
US11559527B2 (en) 2017-12-20 2023-01-24 Lunella Biotech, Inc. Targeting mitochondrial fission through mDIVI-1 derivatives
US20220211728A1 (en) * 2019-04-16 2022-07-07 Lunella Biotech, Inc. Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatments
EP3753944A1 (en) 2019-06-17 2020-12-23 Institute Of Biotechnology Cas, V.V.I. 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE130293T1 (de) * 1990-10-01 1995-12-15 Univ Texas Tamoxifenderivate mit hoher affinität und ihre verwendung.
JP3635708B2 (ja) * 1995-03-06 2005-04-06 出光興産株式会社 有機エレクトロルミネッセンス素子
TWI309571B (en) * 2002-12-31 2009-05-11 Ind Tech Res Inst Delivery carrier for targeting cells haring over-expressed estrogen
KR101003960B1 (ko) * 2003-08-22 2010-12-30 안티포딘 파마슈티칼스, 인코포레이티드 미토콘드리아 표적화 산화방지제로서 사용되는 미토퀴논 유도체를 포함하는 약제학적 조성물
AU2005261654A1 (en) * 2004-07-13 2006-01-19 Oridis Biomed Forschungs- Und Entwicklungs Gmbh Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers
KR101642157B1 (ko) * 2008-03-14 2016-07-22 스티븐 존 랄프 미토콘드리아로 전달되는 항암 화합물
WO2010121177A2 (en) * 2009-04-17 2010-10-21 Colby Pharmaceutical Company Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
WO2011129837A1 (en) * 2010-04-16 2011-10-20 Olema Pharmaceuticals, Inc. Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer

Also Published As

Publication number Publication date
NZ713589A (en) 2017-12-22
PL2989110T3 (pl) 2019-03-29
AU2014256546A1 (en) 2015-11-12
EA029881B1 (ru) 2018-05-31
HRP20181872T1 (hr) 2019-02-08
CN105452265B (zh) 2017-05-10
GEAP201813996A (en) 2018-03-12
MD20150117A2 (ro) 2016-08-31
CY1120821T1 (el) 2019-12-11
EP2989110A1 (en) 2016-03-02
KR101764991B1 (ko) 2017-08-10
CN105452265A (zh) 2016-03-30
EA201591918A1 (ru) 2016-02-29
US20160075726A1 (en) 2016-03-17
HK1216317A1 (zh) 2016-11-04
EP2989110B1 (en) 2018-08-08
KR20150144756A (ko) 2015-12-28
SI2989110T1 (sl) 2019-01-31
MD4626C1 (ro) 2019-11-30
JP2016522179A (ja) 2016-07-28
ES2699099T3 (es) 2019-02-07
GEP20186868B (en) 2018-06-25
PT2989110T (pt) 2018-11-15
DK2989110T3 (en) 2018-12-03
CA2909994A1 (en) 2014-10-30
US9896466B2 (en) 2018-02-20
JP6375091B2 (ja) 2018-08-15
WO2014173374A1 (en) 2014-10-30
AU2014256546B2 (en) 2017-03-30
MD4626B1 (ro) 2019-04-30
UA116469C2 (uk) 2018-03-26
CA2909994C (en) 2018-06-26

Similar Documents

Publication Publication Date Title
IL268987B (en) System for glaucoma treatment
IL264901B (en) Administration of kynurenine depleting enzymes for tumor therapy
IL257978B (en) Use of pasteurized akkermansia for treating metabolic disorders
GEAP201813996A (en) Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level
LT3010910T (lt) Pirimidindiono junginiai, skirti širdies ligoms
IL244422A0 (en) Anti-b7-h1 antibodies for treating tumors
HUE046505T2 (hu) Antitestkészítmények daganatkezelésre
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
PL3283527T3 (pl) Leczenie skojarzone nowotworów
UY34885A (es) Proteínas de unión anti-mesotelina
LT2981255T (lt) Empagliflozino terapiniai panaudojimo būdai
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
HUE046702T2 (hu) Eljárások üvegcsontbetegség kezelésére
HRP20190194T1 (hr) 17a,21-diesteri korteksolona, namijenjeni liječenju tumora
DK3041857T3 (da) Protein a-kromatografi
LT3007726T (lt) Tautopatijos gydymo būdai
HUE046596T2 (hu) Eljárások mitokondriális betegség kezelésére
IL256206A (en) Mct4 inhibitors for treating disease
PT3511004T (pt) Preparações combinadas para o tratamento de cancro
LT3563837T (lt) Terapija bakteriofagu
LT3386997T (lt) Monomaleimidu funkcionalizuoti platinos junginiai, skirti vėžio terapijai
HRP20182041T1 (hr) Pripravci oksprenolola za liječenje raka
HUE047920T2 (hu) GD2-pozitív rák kezelésére szolgáló készítmények
HUE067047T2 (hu) Humán antitest aggrekanáz típusú ADAMTS specieszek ellen aggrekanázzal kapcsolatos betegségek terápiájára
PL3417294T3 (pl) Sposoby obejmujące stałe, przerywane dawkowanie cedyranibu